Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)

This study has been completed.
Sponsor:
Collaborator:
ClinSmart CRO
Information provided by (Responsible Party):
Pharmacosmos A/S
ClinicalTrials.gov Identifier:
NCT01469078
First received: October 27, 2011
Last updated: November 7, 2012
Last verified: November 2012
  Purpose

The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 100 mg, 200 mg or 500 mg in subjects with Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).


Condition Intervention Phase
Chronic Kidney Disease
Drug: Monofer®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)

Resource links provided by NLM:


Further study details as provided by Pharmacosmos A/S:

Primary Outcome Measures:
  • Determination of changes in Iron pharmacokinetic parameters from plasma/serum concentration profile [ Time Frame: From exposure to 7 days post-exposure ] [ Designated as safety issue: No ]
    The follwoing parameter will be determined: AUC0-t, AUC, Cmax, Tmax, Ke, and T1/2


Secondary Outcome Measures:
  • Changes in pharmacodynamic parametres [ Time Frame: From 0 hours to 4, 8, 24, 48, 72 hours post-exposure and end of study visit ] [ Designated as safety issue: No ]
    Changes in the following parametres will be determined: Hemoglobin (Hb), Reticulocyte Count, Reticuloycyte Hemoglobin Content (CHr), Ferritin, Total Iron Binding Capacity (TIBC) and Transferrin Saturation (TfS)

  • Safety evaluation [ Time Frame: From screening to 7 days post-exposure ] [ Designated as safety issue: Yes ]
    The following parameters will be evaluated: Laboratory safety variable, physical examination, vital signs and Electrocardiogram (ECG)


Enrollment: 18
Study Start Date: October 2011
Study Completion Date: November 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 100 mg Monofer® Drug: Monofer®
Single Bolus Injections
Active Comparator: 200 mg Monofer® Drug: Monofer®
Single Bolus Injections
Active Comparator: 500 mg Monofer® Drug: Monofer®
Single Bolus Injections

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women, aged more than 18 years.
  2. Weight above 50 kg.
  3. Subjects diagnosed with CKD-5D and on dialysis therapy for at least 90 days prior to inclusion.
  4. Serum ferritin ≤ 800 ng/mL.
  5. Transferrin Saturation ≤ 35%.
  6. Life expectancy beyond 12 months by Principal Investigator's judgement.
  7. Hb concentrations ≥10.0 g/dL and ≤12.5 g/dL both at Screening Visit 1a and at Screening Visit 1b (Screening Visit 1a and Visit 1b must be separated by at least 1 week).
  8. Erythropoiesis Stimulating Agent (ESA) treatment (to be kept constant during the study period and for 4 weeks prior to inclusion with only one missed dose to be allowed during this pre-entry period).
  9. Subjects in maintenance iron therapy with average iron administration ≤ 100 mg/week for 4 weeks prior to inclusion and willingness to switch to investigational product.
  10. Willingness and ability to participate after informed consent (including HIPAA, if applicable).

Exclusion Criteria:

  1. Anemia caused primarily by other factors than renal related anemia.
  2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis).
  3. Difference of Hb ≥ 1.0 g/dL between Screening Visits 1a and 1b.
  4. Known hypersensitivity to any excipients in the investigational drug products.
  5. Subjects with a history of multiple allergies.
  6. Decompensated liver cirrhosis and history of hepatitis B or C [Alanine Aminotransferase (ALT) > 3 times upper limit of normal].
  7. Acute or chronic infections (assessed by clinical investigator judgment), supported by White Blood Cells (WBC) and C-Reactive Protein (CRP).
  8. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  9. Pregnant or nursing women.
  10. Women of child bearing potential who are not using safe contraceptive methods (e.g. intrauterine device, oral contraceptives or surgically sterilized) or who are planning to become pregnant within the study period.
  11. Blood transfusion within the previous 12 weeks.
  12. Planned elective surgery during the study where significant blood loss is expected.
  13. Participation in any other clinical trial within 3 months prior to screening.
  14. Untreated Vitamin B12 or folate deficiency.
  15. Any other medical condition that, in the opinion of Principal Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study. Examples include Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Pharmacosmos A/S
ClinicalTrials.gov Identifier: NCT01469078     History of Changes
Other Study ID Numbers: P-Monofer-PK-CKD-05
Study First Received: October 27, 2011
Last Updated: November 7, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pharmacosmos A/S:
Chronic Kidney Disease
CKD stage 5
Iron deficiency

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency
Ferric Compounds
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014